Logo-aim
Arch Iran Med. 2020;23(9): 614-620.
doi: 10.34172/aim.2020.72

Scopus ID: 85091809289
  Abstract View: 167
  PDF Download: 170

Systematic Review

An Updated Meta-analysis on the Risk of Urologic Cancer in Patients with Systemic Lupus Erythematosus

Jina Yeo 1 ORCID logo, Min-Seok Seo 2,3 ORCID logo, In Cheol Hwang 4* ORCID logo, Jae-Yong Shim 3 ORCID logo

1 Rheumatology Division, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea
2 Department of Family Medicine, Incheon St. Mary’s Hospital, Incheon, Republic of Korea
3 Yonsei University Graduate School of Medicine, Seoul, Republic of Korea
4 Department of Family Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea
*Corresponding Author: In Cheol Hwang, PhD; Gil Medical Center, Gachon University College of Medicine, 1198 Guwol-dong, Namdong-gu, Incheon 405-760, Republic of Korea. Tel: +82324603354; Fax: +82324603354; Email: spfe0211@gmail.com

Abstract

Background: The risk of urologic cancers in patients with systemic lupus erythematosus (SLE) remains uncertain. We investigated the association between SLE and incident urologic cancers through a systematic review and meta-analysis.

Methods: We searched the PubMed, EMBASE, and the Cochrane Library to identify articles that recorded prostate, bladder, or kidney cancers in SLE patients from inception to August 31, 2018. We included observational, case-control, or cohort studies with no language restriction. Two investigators screened and extracted the data independently.

Results: Fourteen cohort studies with 83,860 SLE patients were finally analyzed. Overall, SLE patients were at increased risk of bladder cancer (hazard ratio [HR], 1.92; 95% confidence interval [CI], 1.15–3.21) but not of prostate or kidney cancer. However, subgroup analyses showed a reduced risk of prostate cancer in <10-year follow-up studies (HR, 0.68; 95% CI, 0.51–0.89) and an elevated risk of kidney cancer in patients with SLE in Western studies (HR, 2.00; 95% CI, 1.02–3.92), community-based studies (HR, 4.54; 95% CI, 2.17–9.52), prospective studies (HR, 6.84; 95% CI, 2.71–17.26), <10-year follow-up studies (HR, 1.88; 95% CI, 1.38–2.57), and low-quality studies (HR, 2.05; 95% CI, 1.50–2.80).

Conclusion: This study indicates that SLE increases the risk of bladder cancer but not prostate or kidney cancer. Well-designed long-term studies are required to confirm these associations.

Keywords: Bladder cancer, Kidney cancer, Meta-analysis, Prostate cancer, Systemic lupus erythematosus
Cite this article as: Yeo J, Seo MS, Hwang IC, Shim JY. An updated meta-analysis on the risk of urologic cancer in patients with systemic lupus erythematosus. Arch Iran Med. 2020;23(9):614–620. doi: 10.34172/aim.2020.72.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 167

Your browser does not support the canvas element.


PDF Download: 170

Your browser does not support the canvas element.

Submitted: 29 Jul 2019
Accepted: 22 Apr 2020
ePublished: 01 Sep 2020
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)